Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.

ABSTRACT:

Aim

A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory.

Methodology

Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated.

Results

In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h.

Conclusion

SUBMITTER: Bergmeijer TO 

PROVIDER: S-EPMC6021912 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature